Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. “This is a really ...

We built our IPO process in partnership with the investment banking community, ensuring that they have the control and information they need to successfully open your IPO. Nasdaq’s best-in-class ...